(Val-)Ganciclovir prophylaxis reduces Epstein-Barr virus primary infection in pediatric renal transplantation

Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in kidney recipients in the United States

(2010) Scott C. Quinlan et al.   AMERICAN JOURNAL OF HEMATOLOGY

The Efficacy and Safety of 200 Days Valganciclovir Cytomegalovirus Prophylaxis in High-Risk Kidney Transplant Recipients

(2010) A. Humar et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Subclinical Viremia Increases Risk for Chronic Allograft Injury in Pediatric Renal Transplantation

(2010) J. M. Smith et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

International Consensus Guidelines on the Management of Cytomegalovirus in Solid Organ Transplantation

(2010) Camille N. Kotton et al.   TRANSPLANTATION

Valganciclovir Dosing According to Body Surface Area and Renal Function in Pediatric Solid Organ Transplant Recipients

(2009) W. Vaudry et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Epidemiology of Pretransplant EBV and CMV Serostatus in Relation to Posttransplant Non-Hodgkin Lymphoma

(2009) Gerhard Opelz et al.   TRANSPLANTATION

A Phase I Trial of Epstein-Barr Virus Gp350 Vaccine for Children With Chronic Kidney Disease Awaiting Transplantation

(2009) Lesley Rees et al.   TRANSPLANTATION

Incidence of PTLD in Pediatric Renal Transplant Recipients Receiving Basiliximab, Calcineurin Inhibitor, Sirolimus and Steroids

(2008) R. A. McDonald et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Detection of Herpesvirus DNA in Cerebrospinal Fluid and Correlation with Clinical Symptoms

(2008) A. Plentz et al.   INFECTION